企業概要
American Shared Hospital Services is a specialized entity within the healthcare sector, specifically focusing on the provision of technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment. The company operates through two distinct business segments, Leasing and Retail, managing the leasing of nine Gamma Knife systems alongside a single proton beam radiation therapy (PBRT) system. As a listed entity under the ticker AMS, the firm currently holds a market capitalization of $8.78M and reports annual revenue of $28.08M, though specific employee headcount data is not disclosed in available records. These valuation figures indicate that the company operates as a micro-cap entity with a relatively small market footprint compared to larger regional hospital operators. The revenue scale suggests a niche operational focus where the company leverages high-value medical equipment rather than managing a broad network of facilities, positioning it as a specialized asset manager within the medical care facilities industry.
財務健全性
The company reported revenue of $28.08M over the trailing twelve months, yet this generated a net income loss of $-1,553,000, revealing a significant gap between top-line generation and profitability driven by high operating expenses. While the company achieved an EBITDA of $3.70M, indicating underlying operational cash generation before interest and taxes, the net income figure reflects substantial interest expenses or one-time costs that erode overall profitability. Free cash flow stands at $-3,995,500, which signals that the company is burning cash and lacks the current financial flexibility to fund capital expenditures without external financing or asset divestitures. The gross margin is recorded at 38.3%, which is healthy for an equipment leasing model, but the operating margin of -14.0% and profit margin of -5.5% highlight severe inefficiencies in managing overhead costs relative to revenue. On the balance sheet, the company holds $3.46M in cash against $21.67M in total debt, resulting in a debt-to-equity ratio of 78.27, which indicates a highly leveraged financial structure. The current ratio is 0.76, suggesting that the company's current assets are insufficient to cover its current liabilities without relying on external funding or asset sales. Return on equity is -9.4% and return on assets is -2.2%, metrics that demonstrate that management has been ineffective at generating returns on the capital invested in the business over the trailing period.
バリュエーション評価
The valuation metrics present a complex picture, with the forward P/E ratio at 3.33 while the trailing P/E ratio is not available due to the net loss, implying that analysts or the market is pricing in a potential future recovery in earnings rather than historical performance. The price-to-book ratio is 0.36, which indicates that the market values the company at a significant discount to its net asset book value, often seen in distressed or turnaround situations. Additionally, the price-to-sales ratio is 0.31 and the EV/EBITDA multiple is 8.28, suggesting that the market is valuing the company based on low multiples typical of high-risk or cyclical sectors rather than stable growth stocks. The stock has a 52-week high of $3.11 and a 52-week low of $1.29, meaning the current trading price sits at the lower end of this range and reflects recent downward pressure on the share price. The beta value is 0.29, indicating that the stock exhibits low volatility relative to the broader market and is less sensitive to general market fluctuations than large-cap healthcare peers.
Growth & Income
Revenue growth year-over-year has contracted by -14.8%, and earnings growth is not applicable given the reported net loss, indicating that the company is currently shrinking rather than expanding its top line. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders and instead retains all earnings, although the negative net income means there are no earnings to reinvest. The absence of a dividend yield combined with negative earnings growth suggests that the company is not in a growth phase but is rather in a contractionary phase where capital preservation is the primary objective. Overall, the growth and income profile is characterized by revenue decline, significant cash burn, and a lack of shareholder returns, presenting a high-risk scenario typical of distressed micro-cap healthcare assets.